



Universiteit
Leiden
The Netherlands

Systemic sclerosis: can we identify patients at risk?

Leeuwen, N.M. van

Citation

Leeuwen, N. M. van. (2022, March 17). *Systemic sclerosis: can we identify patients at risk?*. Retrieved from <https://hdl.handle.net/1887/3279178>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3279178>

Note: To cite this publication please use the final published version (if applicable).

**SYSTEMIC SCLEROSIS:
CAN WE IDENTIFY PATIENTS AT RISK?**

Nina Marijn van Leeuwen

Nina Marijn van Leeuwen
Systemic Sclerosis: can we identify patients at risk?

ISBN: 978-94-6416-101-4
<https://orcid.org/0000-0003-4228-012X>

Cover & Lay out by © evelienjagtman.com
Printed by Ridderprint | www.ridderprint.nl

Financial support by ChipSoft, UCB pharma BV, NVLE fonds, Boehringer Ingelheim

@2022 Nina Marijn van Leeuwen. All right reserved. No part of this study may be reproduced, stored in a retrival system, or transmitted, in any form or by any means, electronically, mechanically, by photocopying, recording or otherwise, without the prior written permission of the author.

SYSTEMIC SCLEROSIS: CAN WE IDENTIFY PATIENTS AT RISK?

Proefschrift

Ter verkrijging van de graad van Doctor
aan de Universiteit Leiden op gezag van de
Rector Magnificus Prof.dr.ir. H. Bijl,
volgens besluit van het College voor Promoties
ter verdedigen op 17 Maart 2022 klokke 13.45

Door

Nina Marijn van Leeuwen

Geboren te Wormerveer in 1991

Promotor:

Prof.dr. T.W.J. Huizinga

Copromotor:

Dr. J.K de Vries-Bouwstra

Leden promotiecommissie:

Prof.dr. R.E.M. Toes

Dr. A.M Hoffmann-Vold, Oslo Universitair Ziekenhuis, Noorwegen

Prof. dr. J.M van Laar, Universitair Medisch Centrum Utrecht

Dr. M.C Vonk, Radboud Universitair Medisch Centrum

TABLE OF CONTENTS

General introduction and outline	7
<hr/>	
PART I : Impact of Systemic Sclerosis	
<hr/>	
1. Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: a focus group study	23
2. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants	45
<hr/>	
PART II: Disease progression in Systemic Sclerosis	
<hr/>	
3. Disease progression in systemic sclerosis	67
4. Gastro-intestinal symptom severity and progression in systemic sclerosis	77
5. A new risk model is able to identify patients with a low risk of progression in systemic sclerosis.	111
<hr/>	
PART III: Role of microangiopathy and specific autoantibodies in Systemic Sclerosis	
<hr/>	
6. The contribution of sex and auto-antibodies to microangiopathy assessed by nailfold videocapillaroscopy in systemic sclerosis: a systematic review of the literature	135
7. Degree of vasculopathy in systemic sclerosis patients with anti-U3RNP antibody indicates need for extensive cardiopulmonary screening	161
8. Association between centromere and topoisomerase specific immune responses and the degree of microangiopathy in systemic sclerosis	169
9. Analyses of anti-centromere antibody levels and isotypes in development of systemic sclerosis	191
<hr/>	
PART IV: Appendices	
<hr/>	
Summary, conclusions and future perspectives	215
Nederlandse samenvatting	233
Curriculum Vitae	249
Woord van dank	255